{
    "eid": "2-s2.0-85013031091",
    "title": "Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial",
    "cover-date": "2017-07-01",
    "subject-areas": [
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        },
        {
            "$": "Immunology and Allergy",
            "@code": "2723"
        },
        {
            "$": "Transplantation",
            "@code": "2747"
        }
    ],
    "keywords": [
        "calcineurin inhibitor (CNI)",
        "cardiovascular disease",
        "clinical research/practice",
        "clinical trial",
        "immunosuppressant",
        "immunosuppressant",
        "immunosuppression/immune modulation",
        "kidney (allograft) function/dysfunction",
        "kidney transplantation/nephrology",
        "mechanistic target of rapamycin: everolimus"
    ],
    "authors": [
        "J. W. de Fijter"
    ],
    "citedby-count": 68,
    "ref-count": 31,
    "ref-list": [
        "Chronic renal allograft injury: Early detection, accurate diagnosis and management",
        "Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation",
        "Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients",
        "Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials",
        "Inhibition of the mTOR pathway: A possible protective role in coronary artery disease",
        "Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload",
        "Rapamycin attenuates load-induced cardiac hypertrophy in mice",
        "Beneficial Effects of Mammalian Target of Rapamycin Inhibition on Left Ventricular Remodeling After Myocardial Infarction",
        "Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft",
        "Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients",
        "Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis",
        "Switch of immunosuppression from cyclosporine A to everolimus: Impact on pulse wave velocity in stable de-novo renal allograft recipients",
        "Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine",
        "A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients",
        "Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation",
        "Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial",
        "Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study",
        "Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial",
        "ELEVATE: An innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus",
        "A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation",
        "Fibrosis progression according to epithelial-mesenchymal transition profile: A randomized trial of everolimus versus CsA",
        "Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen",
        "Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies",
        "Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors",
        "Renal function three years after early conversion from a calcineurin inhibitor to everolimus: Results from a randomized trial in kidney transplantation",
        "Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation",
        "Does everolimus increase donor-specific HLA antibodies in kidney transplant recipients?",
        "The influence of immunosuppressive agents on the risk of de novo Donor-Specific HLA antibody production in solid organ transplant recipients",
        "Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients - a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial",
        "Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation",
        "Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients"
    ],
    "affiliation": [
        {
            "affiliation-city": "Oslo",
            "affilname": "Rikshospitalet-Radiumhospitalet HF",
            "affiliation-country": "Norway"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Buenos Aires",
            "affilname": "Ministerio de Salud",
            "affiliation-country": "Argentina"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Cl\u00ednic de Barcelona",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Berlin",
            "affilname": "Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Khon Kaen",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital del Mar",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Leiden",
            "affilname": "Leids Universitair Medisch Centrum",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Universitari de Bellvitge",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Adelaide",
            "affilname": "The University of Adelaide",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Groningen",
            "affilname": "Universitair Medisch Centrum Groningen",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Heidelberg",
            "affilname": "Universit\u00e4tsklinikum Heidelberg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Amsterdam",
            "affilname": "Universiteit van Amsterdam",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Bangalore",
            "affilname": "Columbia Asia Hospital",
            "affiliation-country": "India"
        }
    ],
    "funding": [
        "Pr Michael Mihatsch",
        "Novartis"
    ]
}